Welcome to our dedicated page for DAVITA SEC filings (Ticker: DVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DaVita Inc. filings document the operating results, governance and capital structure of a public kidney care and dialysis services company. Its 8-K reports furnish quarterly financial results, including revenue, operating income, per-share results, cash flow measures, treatment economics and share repurchase activity.
Proxy filings cover board matters, executive compensation, shareholder voting items and governance disclosures. Other current reports record material financing arrangements, amendments to secured credit facilities, share repurchase authorizations and the company's common stock listing on the New York Stock Exchange under DVA.
DaVita Inc. reported a large shareholder transaction involving entities affiliated with Berkshire Hathaway Inc. and Warren E. Buffett. On January 29, 2026, they reported the sale of 1,658,480 shares of DaVita common stock at $120.5561 per share, reported as indirectly owned.
After this sale, they reported indirect beneficial ownership of 30,100,585 DaVita shares. Of this total, 15,126,977 shares are owned by Government Employees Insurance Company, a Berkshire subsidiary. Another 14,973,608 shares are held by pension plans of Berkshire subsidiaries. Berkshire and Mr. Buffett may be deemed beneficial owners but expressly disclaim beneficial ownership except to the extent of any pecuniary interest.
DaVita Inc. filed a current report to announce that it has issued a press release with its financial results for the quarter ended December 31, 2025. The company furnished this earnings release as an exhibit rather than filing it, which limits how it is treated under securities laws.
The report identifies the press release as Exhibit 99.1 and confirms that DaVita’s common stock continues to trade on the New York Stock Exchange under the symbol DVA.
DaVita Inc. reported an insider equity transaction by its Chief Compliance Officer. On 12/04/2025, the officer exercised stock appreciation rights covering 5,875 shares of DaVita common stock at a base price of $108.93 per share, receiving shares instead of cash. On the same date, 5,412 shares of common stock were disposed of at $118.25 per share, and an additional 203 shares were withheld at $118.25 per share to cover tax obligations related to the exercise.
After these transactions, the officer beneficially owned 26,298 shares of DaVita common stock in direct form. The stock appreciation rights used in this exercise were originally granted on March 15, 2021 and vested in two equal installments on March 15, 2024 and March 15, 2025.
DaVita Inc. entered into an Eighth Amendment to its existing Credit Agreement, adding a new five-year secured term loan A facility of up to $2 billion and a new five-year secured revolving credit facility of up to $1.5 billion. These new facilities are designed to refinance amounts outstanding under the company’s prior term loan A and revolving credit facilities that were scheduled to mature in April 2028.
Borrowings can be made in U.S. dollars, euros, or pounds sterling, with interest based on benchmark rates such as Term SOFR, EURIBOR, or Daily Simple SONIA plus an Applicable Margin. The initial margin is 150 basis points for benchmark-based loans and 50 basis points for Base Rate loans, with both the margin and the undrawn commitment fee later tied to a leverage ratio grid after financial statements for the quarter ending March 31, 2026 are delivered. The new term loan amortizes quarterly starting March 31, 2026, and proceeds are allocated to repay the prior facilities, pay related fees and expenses, and support working capital and general corporate purposes, including potential stock repurchases, acquisitions, and investments.
DaVita Inc. (DVA) director reports stock acquisition. A director of DaVita Inc. reported acquiring 411 shares of the company’s common stock on 11/15/2025 in a transaction priced at $0 per share, as disclosed on a Form 4. Following this transaction, the director beneficially owns 13,981 shares of DaVita common stock, held directly.
DaVita Inc. director reports a small stock acquisition. A DaVita Inc. (DVA) director filed a Form 4 reporting the acquisition of 411 shares of common stock on 11/15/2025 at a reported price of $0 per share. After this transaction, the director holds 411 shares as a direct owner and 2,894 shares as an indirect owner through the Wendy L. Schoppert Revocable Trust. No derivative securities were reported in this filing.
DaVita Inc. director reports a small stock acquisition. A director of DaVita Inc. (DVA) acquired 411 shares of common stock on 11/15/2025 at a reported price of $0 per share, indicating this was likely an equity grant rather than an open-market purchase. Following this transaction, the director beneficially owns 5,110 shares of DaVita common stock, held directly. No derivative securities such as options or warrants are reported as acquired or disposed of in this filing.
A DaVita Inc. (DVA) director reported acquiring 411 shares of common stock on 11/15/2025 at a stated price of $0, indicating this was likely a stock grant rather than an open-market purchase. Following this transaction, the director beneficially owns 2,089 DaVita shares, held in direct ownership. This is a routine insider ownership update showing a modest increase in the director’s equity stake.
DaVita Inc. director reports stock acquisition
A director of DaVita Inc. (DVA) reported acquiring 411 shares of DaVita common stock on 11/15/2025 in a transaction priced at $0 per share. After this transaction, the director beneficially owns 7,231 shares of DaVita common stock in direct ownership. This is a routine insider ownership update, disclosing the director’s latest equity position in the company.
DaVita Inc. director reports small stock acquisition
A director of DaVita Inc. (DVA) reported acquiring 411 shares of DaVita common stock on 11/15/2025 in a Form 4 filing. The shares were acquired at a stated price of $0, which typically indicates an equity award rather than an open-market purchase. Following this transaction, the director now beneficially owns 6,023 shares of DaVita common stock, held directly.